Hunan Hansen Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002412.SZ

Hunan Hansen Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: 14.22

Hunan Hansen Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) is 14.22 on January 27, 2025, a -0.29% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Hunan Hansen Pharmaceutical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 16.02 on October 08, 2024, which is 12.59% above the current Price to Earnings Ratio (P/E).
Hunan Hansen Pharmaceutical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 10.34 on February 07, 2024, which is -27.31% below the current Price to Earnings Ratio (P/E).
Hunan Hansen Pharmaceutical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 13.66.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shenzhen Stock Exchange: 002412.SZ

Hunan Hansen Pharmaceutical Co., Ltd.

CEO	Mr. Zhengqing Liu
IPO Date	May 25, 2010
Location	China
Headquarters	No. 2688, Yincheng Avenue
Employees	1,536
Sector	Health Care
Industries Pharmaceuticals

Description

Hunan Hansen Pharmaceutical Co., Ltd. produces and sells Chinese and chemical medicine preparations in China and internationally. It provides medicines in injection, oral liquid, tablet, capsule, granule, syrup, decoction, tincture, and pill forms. The company is based in Yiyang, China.

Key trends

Past 5 years